Abstract:Background: Treponema pallidum particle agglutination assay (TPPA) has been shown to be highly sensitive and specific at detecting treponemal antibodies and is still used as a confirmatory method in many laboratories, in China. In clinical practice, we found that a significant number of TPPA-negative sera were identified when TPPA was used as a confirmatory assay of Architect chemiluminescent microparticle immunoassay (CMIA) screening-reactive sera. Aims: To investigate the consistency between Architect CMIA and TPPA, and analyzed the characterization of TPPA-negative sera following Screening by Architect CMIA. Methods: According to the laboratory syphilis confirmatory testing protocol, a total of 4870 sera were initially tested by Architect CMIA and ELISA, and then the samples which shown positive results were tested by TPPA and rapid plasma reagin tests (RPR). Further analysis using Euroimmun dot-immunoblot (dot-IBT) assay was performed to the CMIA positive and TPPA negative samples. Results: In our cohort, we found that the positive rate of CMIA was 3.1% (149/4870). One hundred and twelve of 112 (75.2%) CMIA-positive sera were TPPA reactive, while 37 (24.8%) sera which were reactive in CMIA were nonreactive by TPPA. Dot-IBT testing was performed on these 37 sera: 8 (21.6%) were dot-IBT positive, 11 (29.7%) were indeterminate and 18 (48.6%) negative. Discussion: In this study, we observed that 18 CMIA-positive sera were false positives confirmed by dot-IBT. But, given the relatively high levels of early syphilis, we consider a small increase in the number of confirmatory tests is worthwhile if we can increase the detection of primary syphilis by 20%. We also found that significant numbers (8/37) of CMIA-positive and TPPA-negative sera were shown by further dot-IBT testing to be positive. The reason why certain sera are negative by TPPA but reactive by CMIA and other syphilis confirmatory assays is not clear, and these initial findings should be further explored. Conclusion: The Architect CMIA is a highly sensitive screening assay for detecting syphilis but it is significantly less specific. Further analysis by TPPA is recommended to confirm the results. We would highlight the fact that in repeatedly screened populations discrepancies between treponemal CMIA and TPPA results are quite prevalent. This seems to be a function of very low levels of syphilis-specific antibodies. Confirmation by immunoblot assay may be useful.

Evaluation of the HISCL Anti-Treponema pallidum Assay as a Screening Test for Syphilis

Immunohistochemistry detection of Treponema pallidum and its clinical significance

Clinical Evaluation of a New Chemiluminescence Assay for the Detection of Treponema Pallidum Antibodies

Performance Evaluation of CLIA for Treponema Pallidum Specific Antibodies Detection in Comparison with ELISA

Comparison and evaluation of Abbott chemiluminescent microparticle immunoassay and ChIVD light-initiated chemiluminescent assay in the detection of Treponema pallidum antibody

Screening for Antibodies Against Treponema Pallidum with Chemiluminescent Microparticle Immunoassay: Analysis of Discordant Serology Results and Clinical Characterization.

Comparison of "Lumipulse anti-Treponema pallidum" and "Architect Syphilis TP" and further examination

The Tradition Algorithm Approach Underestimates the Prevalence of Serodiagnosis of Syphilis in HIV-infected Individuals

Sensitive and Specific ELISA Coated by TpN15-TpN17-TpN47 Fusion Protein for Detection of Antibodies to Treponema Pallidum.

[Study on ELISAs with Rtpn17, Rtpn47 and Its Fusion Protein As Antigens in the Detection of Serum Samples from Syphilis Patients].

Evaluating the clinical utility of semi-quantitative luciferase immunosorbent assay using Treponema pallidum antigens in syphilis diagnosis and treatment monitoring

[Recombinant Expression of the Fusion Antigen Based on Treponema Pallidum TpN17 and TpN47 Epitope Peptides and Establishment and Application of the Associated ELISA].

A multi-country comparative study of two treponemal tests for the serodiagnosis of syphilis amongst men who have sex with men (MSM): Chemo-luminescent assay vs Treponema pallidum particle agglutination assay

Comparative study of five analytical methods for screening of antibodies against treponema pallidum

Performance of Treponemal Tests for the Diagnosis of Syphilis

Expression of recombinant TpN17 antigen and preliminary application for syphilis diagnosis

Comparison of serological detection effects of ELISA using rTpN17 or rTpN47 of Treponema pallidum as antigen with that of TPHA and TRUST]

Screening for Syphilis with Dual Algorithms: Analysis of Discordant and Concordant Serology Results in a Population with a Low Prevalence of Syphilis.

Consistency Between Treponema pallidum Particle Agglutination Assay and Architect Chemiluminescent Microparticle Immunoassay and Characterization of Inconsistent Samples

Improved efficiency using sequential automated immunoassays for syphilis screening in blood donors

Serological evaluation of recombinant protein antigen Tp0608 for the diagnosis of syphilis